GeneMatrix Inc (KQ:109820) — Market Cap & Net Worth
Market Cap & Net Worth: GeneMatrix Inc (109820)
GeneMatrix Inc (KQ:109820) has a market capitalization of $17.78 Million (₩26.23 Billion) as of August 1, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #25416 globally and #1843 in its home market, demonstrating a -7.66% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GeneMatrix Inc's stock price ₩1314.00 by its total outstanding shares 19964163 (19.96 Million). See GeneMatrix Inc (109820) reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
GeneMatrix Inc Market Cap History: 2015 to 2026
GeneMatrix Inc's market capitalization history from 2015 to 2026. Data shows change from $29.13 Million to $17.78 Million (-3.85% CAGR).
Index Memberships
GeneMatrix Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$181.83 Billion | 0.01% | #975 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$181.83 Billion | 0.01% | #975 of 1384 |
Weight: GeneMatrix Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
GeneMatrix Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GeneMatrix Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
GeneMatrix Inc's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $29.13 Million | $5.32 Billion | -$2.02 Billion | 0.01x | N/A |
| 2016 | $46.09 Million | $5.08 Billion | -$3.78 Billion | 0.01x | N/A |
| 2017 | $32.15 Million | $5.19 Billion | -$1.47 Billion | 0.01x | N/A |
| 2018 | $57.23 Million | $4.73 Billion | -$3.11 Billion | 0.01x | N/A |
| 2019 | $28.68 Million | $5.05 Billion | -$1.37 Billion | 0.01x | N/A |
| 2020 | $351.09 Million | $15.90 Billion | $8.03 Billion | 0.02x | 0.04x |
| 2021 | $132.32 Million | $12.11 Billion | -$987.68 Million | 0.01x | N/A |
| 2022 | $54.86 Million | $11.21 Billion | -$8.11 Billion | 0.00x | N/A |
| 2023 | $42.01 Million | $9.81 Billion | -$894.94 Million | 0.00x | N/A |
| 2024 | $36.80 Million | $10.02 Billion | -$3.75 Billion | 0.00x | N/A |
Competitor Companies of 109820 by Market Capitalization
Companies near GeneMatrix Inc in the global market cap rankings as of August 1, 2026.
Key companies related to GeneMatrix Inc by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #85 globally with a market cap of $216.70 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #168 globally with a market cap of $138.56 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #593 globally with a market cap of $45.41 Billion USD ( CN¥310.35 Billion CNY).
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #612 globally with a market cap of $43.83 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #85 | Thermo Fisher Scientific Inc | NYSE:TMO | $216.70 Billion | $576.77 |
| #168 | Danaher Corporation | NYSE:DHR | $138.56 Billion | $196.17 |
| #593 | WuXi AppTec Co Ltd | SHG:603259 | $45.41 Billion | CN¥125.48 |
| #612 | IDEXX Laboratories Inc | NASDAQ:IDXX | $43.83 Billion | $558.80 |
GeneMatrix Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, GeneMatrix Inc's market cap moved from $29.13 Million to $ 17.78 Million, with a yearly change of -3.85%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩17.78 Million | -46.48% |
| 2025 | ₩33.21 Million | -9.74% |
| 2024 | ₩36.80 Million | -12.40% |
| 2023 | ₩42.01 Million | -23.43% |
| 2022 | ₩54.86 Million | -58.54% |
| 2021 | ₩132.32 Million | -62.31% |
| 2020 | ₩351.09 Million | +1124.06% |
| 2019 | ₩28.68 Million | -49.88% |
| 2018 | ₩57.23 Million | +77.98% |
| 2017 | ₩32.15 Million | -30.23% |
| 2016 | ₩46.09 Million | +58.20% |
| 2015 | ₩29.13 Million | -- |
End of Day Market Cap According to Different Sources
On Jul 31st, 2026 the market cap of GeneMatrix Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $17.78 Million USD |
| MoneyControl | $17.78 Million USD |
| MarketWatch | $17.78 Million USD |
| marketcap.company | $17.78 Million USD |
| Reuters | $17.78 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GeneMatrix Inc
GeneMatrix Inc. develops diagnostic products for various diseases in the field of molecular diagnostics. The company offers products for hepatitis B, hepatitis C, cervical cancer, sexually transmitted infections, respiratory infections, and gastrointestinal infections; vaccines for preventing various diseases; and new natural pharmaceutical materials for health enhancement and treatment. It also … Read more